Bridgeway Capital Management, LLC Paratek Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.37 - $2.54 $157,550 - $292,100	-115,000 Reduced 51.64%	107,700 $273,000
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.51 $167,000 - $250,999	100,000 Added 81.5%	222,700 $416,000
Q1 2022 May 16, 2022	SELL	$2.94 - $4.77 $102,900 - $166,949	-35,000 Reduced 22.19%	122,700 $364,000
Q4 2021 Feb 14, 2022	BUY	$4.07 - $5.3 $641,839 - $835,810	157,700 New	157,700 $708,000
Q2 2020 Aug 14, 2020	SELL	$2.97 - $5.22 $450,846 - $792,396	-151,800 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.67 - $4.97 $133,500 - $248,500	50,000 Added 49.12%	151,800 $478,000
Q4 2019 Feb 14, 2020	BUY	$2.93 - $4.5 $19,924 - $30,600	6,800 Added 7.16%	101,800 $410,000
Q2 2019 Aug 14, 2019	BUY	$3.47 - $6.32 $329,650 - $600,400	95,000 New	95,000 $379,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.